News Search Results
May 06, 2025, 08:01 ET Syrian American Medical Society (SAMS) Concludes Life-Saving Medical Missions in Jordan and Syria
offered services in 17 locations, treating over 2,500 patients and performing 353 surgeries across specialties including cardiology, dentistry, ophthalmology, ENT, OB-GYN, and plastic surgery. "Our mission wasn't just about delivering care—it was about creating a sustainable impact through education
More news about: The Syrian American Medical Society
May 06, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
4:00 p.m. ETLocation: New York, NY Stifel Virtual Ophthalmology Forum Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ETLocation:
More news about: REGENXBIO Inc.
May 06, 2025, 06:45 ET Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
May 06, 2025, 03:00 ET TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer
ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness
More news about: TFS HealthScience
May 06, 2025, 03:00 ET TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of OMTX705 for Pancreatic Cancer
ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness
More news about: TFS HealthScience
May 05, 2025, 20:00 ET Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
presented orally at the 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). The ARVO Annual Meeting 2025 is the premiere gathering of researchers and physicians in vision and ophthalmology to share the latest research findings and collaborate on innovative solutions, to be
More news about: Innovent Biologics
May 05, 2025, 08:00 ET Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics Ltd.
May 05, 2025, 07:30 ET Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
announced new preclinical data for PL9588, a novel melanocortin receptor agonist, presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The findings support the potential of PL9588 as a topical treatment for glaucoma, combining both IOP-lowering and neuroprotective
More news about: Palatin Technologies, Inc.
May 02, 2025, 16:45 ET Pykus Therapeutics Announces Positive Interim Pilot Clinical Trial Results of PYK-2101, a Novel Retinal Sealant
patients undergoing retinal detachment surgery," said Dean Eliott, MD, Stelios Evangelos Gragoudas Professor of Ophthalmology at Harvard Medical School at Massachusetts Eye and Ear Infirmary, and Director of the Retina Fellowship at Harvard/Mass.
More news about: Pykus Therapeutics
May 01, 2025, 23:43 ET Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah. "We are pleased to share new
More news about: Kodiak Sciences Inc.
May 01, 2025, 09:00 ET Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
understanding of the science of GA, and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 4-8, Salt Lake City, Utah, and Retina World Congress (RWC),
More news about: Astellas Pharma Inc.
May 01, 2025, 08:18 ET Everads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal Injector
five abstracts — including first-in-human data — have been accepted for presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, taking place next week in Salt Lake City, Utah. The Everads Suprachoroidal
More news about: Everads Therapy
Apr 30, 2025, 09:00 ET ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Association for Research in Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS
More news about: Carl Zeiss Meditec AG
Apr 30, 2025, 09:00 ET ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Association for Research in Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS
More news about: Carl Zeiss Meditec AG
Apr 30, 2025, 08:00 ET Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval,
More news about: Mabwell
Apr 30, 2025, 07:00 ET Avista Therapeutics Announces Oral Presentation at Association for Research in Vision and Ophthalmology 2025 Annual Meeting
present data highlighting the potential of its scAAVengr-HUnT platform to develop improved AAV capsids at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah taking place May 4-8, 2025.
More news about: Avista Therapeutics
Apr 29, 2025, 20:00 ET Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced completion of the first patient dosing for IBI3020, its first-in-class dual-payload CEACAM5 ADC, in Phase 1
More news about: Innovent Biologics
Apr 29, 2025, 10:05 ET Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030 at CAGR 5.85% - Grand View Research, Inc.
DiseasesOncologyCNS and NeurologyOrthopedicEndocrinologyPulmonologyGastroenterologyNephrologyOphthalmologyOthersActive Pharmaceutical Ingredients Market - Type of Drug Outlook (Revenue, USD Billion, 2018 - 2030) PrescriptionOTCActive
More news about: Grand View Research, Inc.
Apr 29, 2025, 08:24 ET Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
April 29, 2025 /PRNewswire/ -- Tavo Biotherapeutics, a leading innovator in the ophthalmology industry, today announced the appointment of Lukas Scheibler, Ph.D. as Chief Research and Development Officer, and
More news about: Tavo Biotherapeutics
Apr 29, 2025, 08:00 ET ONE OF THE WORLD'S MOST PRESTIGIOUS CANCER CENTERS ADOPTS SECTRA FOR INTEGRATED DIAGNOSTICS AND IMPROVED PATIENT CARE
The center will initially utilize Sectra's modules for radiology, breast imaging, cardiology, pathology and ophthalmology, all unified within a single platform. A single system for multiple specialties will provide them with a comprehensive overview of the patient imaging
More news about: Sectra, Inc
Apr 29, 2025, 02:49 ET One of the world's most prestigious cancer centers adopts Sectra for integrated diagnostics and improved patient care
improving patient care. The center will initially utilize Sectra's modules for radiology, breast imaging, cardiology, pathology and ophthalmology, all unified within a single platform. A single system for multiple specialties will provide them with a comprehensive overview of the patient imaging
More news about: Sectra
Apr 28, 2025, 08:00 ET Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Apr 28, 2025, 07:00 ET InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.
Apr 28, 2025, 04:00 ET Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics
Apr 28, 2025, 04:00 ET Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics